October 18, 2011

Stock Rating
Overweight
Industry View
In-Line

Oberoi Realty Limited

2Q Earnings Beat, New Launch Pick Up in 2012 - OW

F2Q12 results ahead of our estimate: Sales were up 31% yoy (up 38% qoq; due to higher recognition of Splendor and Exquisite), while operating margins compressed 10 ppts due to project cost revision of Splendor (lower interest charge for payment delays) and upward revision of specs at Exquisite and Grande. This along with higher financial income/higher tax rate led to 17% yoy growth in net profits to Rs 1.1bn (up 21% qoq excluding one offs), above our estimate of Rs0.8bn. Rental income from Oberoi Mall and Commerz I was largely flat qoq (Rs 307 mln) and accounted for 14% of total income. Westin income dropped 9% qoq on account of seasonality.

Operational highlights – New sales momentum was lackluster with 82 units sold during the quarter (Esquire 52, Exquisite 9, Grande 17, Splendor 3) versus 95 units in the previous quarter. Cumulatively, OBER has sold 53%, 29% and 49% in Exquisite, Esquire and Grande (all under construction). It continues to hold 85 units of finished inventory in Splendor. According to management, commercial demand is soft due to which corporate leasing activity is poor (Commerz I – 25% vacant, no progress in Commerz II/Phase I leasing and strata sales likely in Prisma). Importantly, the company has raised base selling price in Grande recently (8-9% to Rs12.5k psf – only above 19th floor) and is planning to do so for Esquire in the near future.

New launches likely in 2012 – Oasis (Worli) hard launch is likely in F4Q12, though soft marketing will continue. Exotica (Mulund) launch is now delayed to mid 2012 given regulatory hurdles and GSK Worli in the next 12 months (subject to resolution of pending issues with BMC). Prisma launch is possible in the ensuing months on strata basis. OBER continues to explore new project opportunities to deploy its surplus cash (Rs12 bln).

We remain OW on OBER in view of its quality brand, strong balance sheet and good visibility to monetize its well-located land bank.

MORGAN STANLEY RESEARCH ASIA/PACIFIC

Morgan Stanley India Company
Private Limited+

Sameer Baisiwala, CFA Sameer.Baisiwala@morganstanley.com

+91 22 6118 2214

Harshal Pandya

Harshal.Pandya@morganstanley.com +91 22 6118 2217

Key Ratios and Statistics

Reuters: OEBO.BO Bloomberg: OBER IN India Property

Shr price, close (Oct 13, 2011)	Rs230.25
52-Week Range	Rs306.60-210.00
Sh out, dil, curr (mn)	328
Mkt cap, curr (mn)	Rs75,576
EV, curr (mn)	Rs61,942
Avg daily trading value (mn)	Rs114

Fiscal Year ending	03/11	03/12e	03/13e	03/14e
ModelWare EPS (Rs)	15.76	15.28	22.64	39.50
Prior ModelWare EPS (Rs)	-	-	-	-
Consensus EPS (Rs)§	16.00	17.01	25.08	35.64
Revenue, net (Rs mn)	-	-	-	-
EBITDA (Rs mn)	6,398	5,897	9,080	16,124
ModelWare net inc (Rs mn)	5,172	5,017	7,431	12,965
P/E	16.0	15.1	10.2	5.8
P/BV	2.5	2.0	1.7	1.3
RNOA (%)	27.1	19.0	27.8	47.0
ROE (%)	28.3	15.1	19.7	29.1
EV/EBITDA	10.8	9.9	5.8	2.6
Div yld (%)	0.0	0.5	0.8	1.2
FCF yld ratio (%)	0.8	5.0	8.0	15.3
Leverage (EOP) (%) Unless otherwise noted, all metrics a	(41.2) are based on	(45.2) Morgan Sta	(50.5) anley Mode	(58.5) Ware

framework (please see explanation later in this note).

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+= Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to NASD/NYSE restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

 ^{§ =} Consensus data is provided by FactSet Estimates.
 e = Morgan Stanley Research estimates

Exhibit 1

OBER: Quarterly Income Statement

Rs. Millions	F2Q12	F2Q11	% Change	F1Q12	% Change
Period Ending	30-Sep-11	30-Sep-10	YoY	30-Jun-11	QoQ
	•				
Net Sales / Income from Operations	2,201	1,700	30%	1,596	38%
Other Operating Income	25	1	2656%	14	84%
Total Income	2,226	1,701	31%	1,609	38%
Expenditure	1,071	694	54%	706	52%
- Operating Expenses	951	564	69%	587	62%
- Employee Cost	85	69	23%	84	1%
- Other Expenditure	35	62	-44%	35	-1%
Operating Profit	1,156	1,006	15%	903	28%
Other Income	343	70	389%	542	-37%
Depreciation and Amortisation	66	58	14%	65	1%
Interest and Finance Charges	0	2		1	-50%
Prior Period Items	0	0		5	
Profit Before Tax	1,432	1,017	41%	1,374	4%
Tax Expenses	317	62	416%	316	0%
Net Profit	1,114	955	17%	1,058	5%
GPM (%)	57%	67%	-10%	64%	-6%
OPM (%)	52%	59%	-7%	56%	-0% -4%
NPM (%)	50%	56%	-6%	66%	-16%
Effective Tax Rate (%)	22%	6%	16%	23%	-1%

Source: Company data, Morgan Stanley Research

Exhibit 2

OBER: Quarterly Cash Flow Statement

Rs. Min	F2Q12	F2Q11	F1Q12
Opening Cash & cash Equivalents	15,646	4,801	13,993
Operating Cash Flows	867	838	549
Investing Cash Flows	(2,886)	(575)	(4,260)
Financing Cash Flows	(158)	(6)	(53)
Closing Cash and Cash Equivalents	13,469	5,058	10,228

Exhibit 3

OBER: Project Wise Sales Details (F4Q11 – F2Q12)

		F	4Q11		F1Q12 F2Q12							
Project	Area sold	Units sold	Sale Value	Effective Rate	Area sold	Units sold	Sale Value	Effective Rate	Area sold	Units sold	Sale Value	Effective Rate
	sq.ft.		Rs.Mil	Rs.psf	sq.ft.		Rs.Mil	Rs.psf	sq.ft.		Rs.Mil	Rs.psf
Splendor	5,922	6	118	19,858	2,961	3	67	22,526	2,961	3	65	21,817
Exquisite	9,230	5	145	15,655	13,250	7	211	15,909	19,500	9	276	14,169
Splendor Grande					27,300	15	368	13,473	30,940	17	413	13,335
Esquire	273,025	109	3,190	11,682	166,835	70	1973	11,828	126,985	52	1486	11,701
Total	288,177	120	3,452	11,978	210,346	95	2,619	12,449	180,386	81	2,239	12,414

Source: Company data, Morgan Stanley Research

Exhibit 4


OBER: Project Wise Cumulative Sales Data (F4Q11 - F2Q12)

	Total		End F	4Q11	End F1	IQ12	End F	2Q12
Project	Saleable Area (msf)	Nos of Units	% Completion	% Sold	% Completion	% Sold	% Completion	% Sold
Splendor	1.28	1296	94%	92.9%	96%	93.2%	100%	93.4%
Exquisite	1.51	786	29%	50%	33%	51%	39%	53%
Splendor Grande	0.28	156	28%	28%	36%	37%	45%	49%
Esquire	1.97	846	<20%	14%	<20%	22%	<20%	29%

Source: Company data, Morgan Stanley Research

Exhibit 5


OBER: F2Q12 Revenue Breakdown by Project



Source: Company data, Morgan Stanley Research

Exhibit 6

OBER: Revenue Trend




MORGAN STANLEY RESEARCH

October 18, 2011 Oberoi Realty Limited

Exhibit '


OBER: Revenue Trend for Rental/Hospitality Assets



Source: Company data, Morgan Stanley Research

Exhibit 8


OBER: Occupancy Trend For Rental/Hospitality Assets



Source: Company data, Morgan Stanley Research

Exhibit 9


OBER: Leasing Trend for Rental Assets



Source: Company data, Morgan Stanley Research

Exhibit 10

OBER: Net Profit Trend



MORGAN STANLEY RESEARCH

October 18, 2011 **Oberoi Realty Limited**

Real Estate Valuation Parameters: Indian Companies

Prices as of Oct 17, 2011	Price	Mkt Cap		EPS			P/E			P/B		R	οE	Fwd	% (Dis)/Prem
	(Rs)	(Rs. mn.)	F2011	F2012E	F2013E	F2011	F2012E	F2013E	F2011E	F2012E	F2013E	F2012E	F2013E	NAV/Share	NAV
Indian Companies															
DLF#	236	394,346	9.1	9.0	10.1	25.6	25.8	23.1	1.6	1.5	1.5	5.9%	6.3%	252	-6.4%
Unitech	27	71,556	2.2	2.4	2.9	12.2	11.4	9.1	0.6	0.6	0.6	5.2%	6.1%	^	^^
Indiabulls Real Estate Ltd. #	72	29,588	3.8	7.9	14.2	19.3	9.1	5.1	0.3	0.3	0.3	3.3%	5.6%	250	-71.1%
Jaypee Infratech Ltd #	61	84,169	10.5	6.8	9.1	5.8	8.9	6.7	1.8	1.5	1.2	17.0%	18.5%	106	-42.8%
DB Realty Ltd.	58	14,121	12.3	19.6	14.7	4.7	3.0	4.0	0.4	0.4	0.4	14.2%	8.9%		
Sobha Developers Ltd.#	231	22,216	18.5	21.0	24.8	13.3	10.8	9.1	1.2	1.1	1.0	10.3%	11.1%	445	-48.1%
Oberoi Realty Ltd.#	235	76,971	15.8	15.3	22.6	14.9	15.3	10.4	2.3	2.0	1.7	13.3%	16.7%	314	-25.3%
HDIL	99	41,189	19.8	22.6	27.0	5.0	4.5	3.7	0.4	0.4	0.4	9.0%	10.0%		
Puravankara Projects Ltd.	73	15,655	5.5	7.6	9.7	13.3	9.7	7.5	1.0	0.9	8.0	9.2%	11.0%		
Mahindra Lifespace Developers	295	11,807	26.2	29.7	40.7	11.0	9.7	7.1	1.1	1.0	0.9	10.1%	12.1%		
Ansal Properties	35	5,438	7.7	8.5	14.3	4.6	4.1	2.5	0.3	0.3	0.3	7.4%	11.6%		
Godrej Properties Ltd. #	666	46,541	18.7	19.4	38.7	35.6	34.4	17.2	5.1	4.6	3.7	13.4%	21.7%	708	-5.9%
AIM Listed companies	(GBp)	(£mn)													
Unitech Corporate Parks*	26	94												^^	^
Hirco PLC*	57	44													
Ishaan*	48	70													
Weighted Average						19.2	18.2	14.9	1.6	1.4	1.3				

Real Estate Valuation Parameters: Regional Companies

10/17/2011	Share	Mkt Cap	<u>F</u>	<u> </u>	<u> </u>	<u>P/B</u>	R	o <u>E</u>	Net D/E	Int. Cov	NAV/	Disc to	Fwd	Disc to
Company	Price	US\$M	2010	2011E	2010	2011E	2010	2011E	2010	2010	share	NAV	NAV	fwd NAV
China Property Stocks														
China Vanke	8.03	13,834	12.4	8.7	2.0	1.7	19%	23%	0.2	10.7	12.0	-33%	10.1	-21%
COLI.	15.56	16,321	12.0	11.7	2.1	2.0	23%	20%	0.2	31.4	-		NA	
Country Garden	3.42	7,185	13.4	12.5	1.8	1.8	15%	16%	0.5	5.7	4.3	-21%	3.9	-12%
Guangzhou R&F	8.41	3,480	8.3	4.5	1.5	1.0	22%	25%	0.9	6.9	23.6	-64%	18.4	-54%
China Resources Land	12.02	7,775	16.8	11.8	1.8	1.4	11%	13%	0.5	15.9	-		NA	
Agile Property	9.84	4,733	9.5	6.7	1.8	1.3	25%	22%	8.0	63.5	19.8	-50%	17.5	-44%
Shanghai Forte Land	3.48	1,130	5.0	5.8	0.7	0.9	18%	17%	1.1	27.5	7.0	-50%	5.1	-31%
Weighted Average			12.4	10.1	1.9	1.7								
HK Property Stocks														
SHK Properties	104.00	34,321	19.8	15.4	1.1	1.1	6%	8%	0.1	30.5	147.0	-29%	158.00	-34%
Hang Lung Properties Ltd.	26.90	15,447	18.7	50.7	1.3	1.3	10%	3%	(0.1)	278.5	26.0	3%	28.0	-4%
Weighted Average			19.5	26.4	1.2	1.2								

Source: Company data, Morgan Stanley Research,

* Prices in pence as on October 17, 2011, Mkt cap in £mn

= Morgan Stanley Research estimates; all others are FactSet consensus E = estimates

** DLF, OBER and GPL NAV is for Mar '12; Sobha, IBREL and JIL NAV are for Mar '11.

M = Stock rating, price target and/or estimates not available or have been removed due to applicable law and/or Morgan Stanley policy.

MORGAN STANLEY RESEARCH

October 18, 2011 Oberoi Realty Limited



Morgan Stanley ModelWare is a proprietary analytic framework that helps clients uncover value, adjusting for distortions and ambiguities created by local accounting regulations. For example, ModelWare EPS adjusts for one-time events, capitalizes operating leases (where their use is significant), and converts inventory from LIFO costing to a FIFO basis. ModelWare also emphasizes the separation of operating performance of a company from its financing for a more complete view of how a company generates earnings.

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Smith Barney Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited and their affiliates (collectively, "Morgan Stanley").

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

Analyst Certification

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Sameer Baisiwala.
Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies.

Important US Regulatory Disclosures on Subject Companies

As of September 30, 2011, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Oberoi Realty Limited, Sobha Developers Ltd., Unitech Corporate Parks Plc, Unitech Limited. Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Oberoi Realty Limited.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from DLF Limited, Godrej Properties Limited, Indiabulls Real Estate Limited, Oberoi Realty Limited, Sobha Developers Ltd., Unitech Limited.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: DLF Limited, Godrej Properties Limited, Indiabulls Real Estate Limited, Oberoi Realty Limited, Sobha Developers Ltd., Unitech Limited, Oberoi Realty Limited, Sobha Developers Ltd., Unitech Limited.

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment

banking revenues.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, fund management, commercial banking, extension of credit, providing liquidity and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of September 30, 2011)

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

	Coverage U	niverse	Investment	nts (IBC)		
_		% of		% of 9	% of Rating	
Stock Rating Category	Count	Total	Count	Total IBC	Category	
Overweight/Buy	1130	40%	457	46%	40%	
Equal-weight/Hold	1168	42%	419	42%	36%	
Not-Rated/Hold	112	4%	23	2%	21%	
Underweight/Sell	400	14%	104	10%	26%	
Total	2,810		1003			

Data include common stock and ADRs currently assigned ratings. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months.

Analyst Stock Ratings

Overweight (O or Over) - The stock's total return is expected to exceed the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months.

Equal-weight (E or Equal) - The stock's total return is expected to be in line with the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months.

Not-Rated (NR) - Currently the analyst does not have adequate conviction about the stock's total return relative to the relevant country MSCI Index on a risk-adjusted basis, over the next 12-18 months.

Underweight (U or Under) - The stock's total return is expected to be below the total return of the relevant country MSCI Index, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant

broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant

broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index.

Stock Price, Price Target and Rating History (See Rating Definitions)



Price Target History: 11/25/10 : 370; 8/31/11 : 345 Date Format : MM/DD/YY No Price Target Assigned (NA) Source: Morgan Stanley Research Price Target --Stock Price (Not Covered by Current Analyst) - Stock Price (Covered by Current Analyst)

Stock and Industry Ratings (abbreviations below) appear as ♦ Stock Rating/Industry View

Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) More Volatile (V) No Rating Available (NA) Industry View: Attractive (A) In-line (I) Cautious (C)

MORGAN STANLEY RESEARCH

October 18, 2011 **Oberoi Realty Limited**

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Citi Investment Research & Analysis (CIRA) research reports may be available about the companies or topics that are the subject of Morgan Stanley Research. Ask your Financial Advisor or use Research Center to view any available CIRA research reports in addition to Morgan Stanley research reports.

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC, Morgan Stanley and Citigroup Global Markets Inc. or any of their affiliates, are available on the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures.

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citigroupgeo.com/geopublic/Disclosures/index_a.html.

Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Client Link at www.morganstanley.com.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments or companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's

Morgan Stanley may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. Information on any securities/instruments issued by a company owned by the government of or incorporated in the PRC and listed in on the Stock Exchange of Hong Kong ("SEHK"), namely the H-shares, including the component company stocks of the Stock Exchange of Hong Kong ("SEHK")'s Hang Seng China Enterprise Index is distributed only to Taiwan Securities Investment Trust Enterprises ("SITE"). The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives.

Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves.

an one to set of the solicitation of an one to buy any securities in the PRC. PRC investors snall nave the felevant query and the responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A.; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia (Singapore) Pet. (Registration number 1992/06/2982) and/or Morgan Stanley Asia (Singapore) Pet. (Registration number 1992/06/2982) and/or Morgan Stanley Asia (Singapore) Securities Pet Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Smith Barney Australia Pty Ltd (A.B.N. 1900) 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley Research in Canada by Morgan Stanley Canada Limited, which has approved of, and has agreed to take responsibility for, the contents of Morgan Stanley Research in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main and Morgan Stanley Private Wealth Management Limited, Nicelarlassung Deutschland, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley Research has been written and distributed in accorptance with the rules of conduct applicable to financial research as established under Spanish regulations; in the United States by Morgan Stanley & Co. LtC, which accepts responsibility for its contents. Morgan Stanley & Co. International

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client.

MORGAN STANLEY RESEARCH

October 18, 2011 Oberoi Realty Limited

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided in accordance with a contract of engagement on investment advisory concluded between brokerage houses, portfolio management companies, non-deposit banks and clients. Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley has based its projections, opinions, forecasts and trading strategies regarding the MSCI Country Index Series solely on publicly available information. MSCI has not reviewed, approved or endorsed the projections, opinions, forecasts and trading strategies contained herein. Morgan Stanley has no influence on or control over MSCI's index compilation decisions.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Morgan Stanley Research is disseminated and available primarily electronically, and, in some cases, in printed form.

Additional information on recommended securities/instruments is available on request.

The Americas 1585 Broadway New York, NY 10036-8293 **United States** Tel: +1 (1) 212 761 4000

20 Bank Street, Canary Wharf London E14 4AD **United Kingdom** Tel: +44 (0) 20 7 425 8000

4-20-3 Ebisu, Shibuya-ku Tokyo 150-6008 Japan Tel: +81 (0) 3 5424 5000

Asia/Pacific 1 Austin Road West Kowloon Hong Kong Tel: +852 2848 5200

Industry Coverage:India Property

Company (Ticker)	Rating (as of) Price* (10/17/2011)								
Sameer Baisiwala, CFA									
DLF Limited (DLF.BO)	E (09/06/2011)	Rs235.85							
Indiabulls Real Estate Limited (INRL.BO)	O (07/01/2010)	Rs72.25							
Jaypee Infratech Limited (JYPE.BO)	E (07/01/2010)	Rs60.6							
Oberoi Realty Limited (OEBO.BO)	O (11/25/2010)	Rs234.5							
Sobha Developers Ltd. (SOBH.BO)	O (05/25/2010)	Rs230.85							
Unitech Corporate Parks Plc (UCP.L)	NA (12/31/2010)	26p							
Unitech Limited (UNTE.BO) Arunabh Chaudhari	NA (12/31/2010)	Rs27.2							
Godrej Properties Limited (GODR.BO)	E (06/28/2011)	Rs666.3							

Stock Ratings are subject to change. Please see latest research for each company. * Historical prices are not split adjusted.